生物活性 | |||
---|---|---|---|
描述 | Recruitment of myeloid-derived suppressor cells (MDSC) into the tumor microenvironment (TME) contributes to cancer immune evasion. MDSCs express the chemokine receptor CXCR2, and inhibiting CXCR2 suppresses the recruitment of MDSCs into the tumor and the premetastatic niche[3]. SX-682, an orally bioavailable small-molecule inhibitor of CXCR1/2 currently undergoing clinical evaluation, could block tumor MDSC recruitment and enhance T cell activation and antitumor immunity following multiple forms of immunotherapy. In mice bearing MOC1 or LLC tumors, SX-682 beginning 10 or 20 days after tumor initiation significantly inhibited trafficking of PMN-MDSCs without altering CXCR2 ligand expression[4]. In mice bearing MOC2 tumors, inhibition of MDSC trafficking with SX-682 (500 mg/kg/day; 1 week) significantly abrogated tumor MDSC accumulation and enhanced the tumor infiltration, activation, and therapeutic efficacy of adoptively transferred murine NK (natural killer) cells[5]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.14mL 0.43mL 0.21mL |
10.70mL 2.14mL 1.07mL |
21.40mL 4.28mL 2.14mL |
参考文献 |
---|